Only a minority of centres have specialist clinics for management of co-morbidities Two-thirds of HIV clinics in the UK do not think there is a current need for specialist care services targeted at older adults, investigators report in HIV Medicine. “This is important as, although there ...

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it received written communication from the U.S. Food and Drug Administration (FDA) that the clinical development program for RG-101 remains on clinical hold. In ...

On December 14 2016, the closing EUPATI workshop named “All Aboard to a Better Health Future” took place in Brussels. The meeting presented the achievements, learnings, goals, work done, accomplishments, as well as plans for the future sustainability and continuation of the EUPATI toolbox, trainings, ...

No new HIV infections have been seen among nearly 1000 people who started Truvada for pre-exposure prophylaxis (PrEP) at Kaiser Permanente Northern California, according to a recent report in the Journal of Acquired Immune Deficiency Syndromes. The most recent analysis shows, however, that incidence of ...

The National Institute for Health and Care Excellence has now published final guidance endorsing Epclusa as an option for the treatment of adults with chronic hepatitis C genotype 1-6 infection on the NHS in England and Wales. Epclusa – a once-daily, fixed-dose combination of the nucleotide ...

Currently most effective directly-acting antiviral agent for hepatitis C (HCV) treatment has already arrived to Ukraine! Alliance for Public Health launches the third phase of HCV treatment program for key populations. This phase stipulates using a direct-acting antiviral agent, which is new for Ukraine – Harvoni ...

Study finds good nutrition improves medication adherence and mental health HIV-positive people who received healthy food and snacks for six months were more likely to adhere to their medication regimens, and they, as well as people with type 2 diabetes, were less depressed and less likely ...

Fervid research has uncovered dozens of antibodies that shield cells from HIV. These broadly neutralizing antibodies (bNAbs) protect monkeys from SHIV, the simian-HIV hybrid. Thousand-person human trials are already dripping bNAbs into high-risk men and women to see if they prevent HIV infection. And much ...

A team led by UCL researchers has identified how HIV is able to infect macrophages, a type of white blood cell integral to the immune system, despite the presence of a protective protein. They discovered a treatment that can maintain macrophage defences which could be ...

Without antiretroviral drug treatment, the majority of people infected with HIV ultimately develop AIDS, as the virus changes and evolves beyond the body’s ability to control it. But a small group of infected individuals—called elite controllers—possess immune systems capable of defeating the virus. They accomplish ...

In an effort to improve the international response to combatting multidrug-resistant TB, MPP and Johns Hopkins University sign licensing agreement for investigational treatment sutezolid Geneva, 25 January 2017 — The Medicines Patent Pool today announced that it has signed a licence with Johns Hopkins University ...

The Russian Health Ministry has abandoned a proposal to allocate additional funding to the fight against the spread of HIV. According to the RBC news agency, the ministry submitted a four-year plan to the federal government this week that does not include a proposal to ...

European Medicines Agency grants accelerated assessment, validates Marketing Authorization Application for AbbVie’s investigational regimen of glecaprevir/pibrentasvir (G/P) for the treatment of chronic hepatitis C in all major genotypes (GT1-6) – If approved, G/P may provide a shorter, eight week, once-daily, ribavirin-free treatment option for the majority ...

Around one in six young and middle-aged HIV-positive men doing well on antiretroviral therapy (ART) had low testosterone levels, French investigators report in the online edition of AIDS. Overall, 12% of the sample had low testosterone, or male hypogonadism. Risk factors were longer duration of ...

Gene therapy — which involves modifying genetic material, such as DNA and RNA — holds exciting potential as a cure for numerous diseases and conditions, including HIV. Timothy Brown (the “Berlin patient”) remains the only person known to have been cured of HIV. Brown received a ...

In 2016, countries of the WHO European Region recognized that the Health 2020 policy framework and related World Health Assembly and Regional Committee resolutions provide a strong foundation upon which to position health at the centre of initiatives to implement the 2030 Agenda for Sustainable ...

A group of researchers is investigating whether or not interferon-free therapy could reverse the cognitive declines that appear to accompany infection with the hepatitis C virus (HCV), with or HIV coinfection. Felix Kleefeld, of Berlin, Germany, and colleagues examined how eradicating HCV affected the cognition of ...

Initiating, rather than deferring, antiretroviral therapy (ART) reduces the risk of severe bacterial infections in HIV-positive individuals with high CD4 counts, researchers say. Their data are from the START trial, which showed a 57% reduction in the risk of AIDS and non-AIDS morbidity and mortality in ...